Biotinylated SARS-CoV-2 Spike RBD Alpha Variant

• Description:

  Biotinylated SARS-CoV-2 Spike RBD Alpha Variant_x000D_ Catalog number: B2010501_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 25 ug_x000D_ Molecular Weight or Concentration: 27 kDa_x000D_ Supplied as: Lyophilized Powder_x000D_ Applications: molecular component of many serological and antigenic assays for SARS-CoV-2 and its variants_x000D_ Storage: -20℃_x000D_ Keywords: Alpha Variant Spike, B.1.1.7 Spike RBD, Alpha RBD, biotin ALPHA RBD_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ Download SARS-CoV-2 Brochure_x000D_ _x000D_ References:_x000D_ 1: Wilson P, Changrob S, Fu Y, Guthmiller J, Halfmann P, Li L, Stamper C, Dugan_x000D_ H, Accola M, Rehrauer W, Zheng NY, Huang M, Wang J, Erickson S, Utset H, Graves_x000D_ H, Amanat F, Sather DN, Krammer F, Kawaoka Y. Cross neutralization of emerging_x000D_ SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on_x000D_ spike. Res Sq [Preprint]. 2021 Jul 19:rs.3.rs-678247._x000D_ _x000D_ 2: Sinegubova MV, Orlova NA, Kovnir SV, Dayanova LK, Vorobiev II. High-level_x000D_ expression of the monomeric SARS-CoV-2 S protein RBD 320-537 in stably_x000D_ transfected CHO cells by the EEF1A1-based plasmid vector. PLoS One. 2021 Feb_x000D_ 2;16(2):e0242890._x000D_ _x000D_ 3: Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And_x000D_ Novel Therapeutics Against Coronavirus (COVID-19). 2021 Jul 18. In: StatPearls_x000D_ [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–._x000D_ _x000D_ 4: Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH,_x000D_ Composto K, Chow KF, Kordalewska M, Corvelo A, Oschwald DM, Fennessey S,_x000D_ Zetkulic M, Dar S, Kramer Y, Mathema B, Germer S, Stone M, Simmons G, Busch MP,_x000D_ Maniatis T, Perlin DS, Kreiswirth BN. Emergence of Multiple SARS-CoV-2 Antibody_x000D_ Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma_x000D_ Treatment. mSphere. 2021 Aug 25;6(4):e0048021._x000D_ _x000D_ 5: Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P,_x000D_ Navarro MJ, Lai L, Edara VV, Röltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn_x000D_ S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M,_x000D_ Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C,_x000D_ Dufour J, Spencer S, Doyle-Meyers L, Bohm RP, Maness NJ, Roy C, Plante JA,_x000D_ Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O'Hagan DT,_x000D_ Van Der Most R, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S,_x000D_ Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport_x000D_ J, Suthar MS, King NP, Veesler D, Pulendran B. Adjuvanting a subunit COVID-19_x000D_ vaccine to induce protective immunity. Nature. 2021 Jun;594(7862):253-258._x000D_ _x000D_ 6: Zhang Z, Zeng E, Zhang L, Wang W, Jin Y, Sun J, Huang S, Yin W, Dai J, Zhuang_x000D_ Z, Chen Z, Sun J, Zhu A, Li F, Cao W, Li X, Shi Y, Gan M, Zhang S, Wei P, Huang_x000D_ J, Zhong N, Zhong G, Zhao J, Wang Y, Shao W, Zhao J. Potent prophylactic and_x000D_ therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection_x000D_ in vivo. Cell Discov. 2021 Aug 12;7(1):65._x000D_ _x000D_ 7: Mohammadi M, Shayestehpour M, Mirzaei H. The impact of spike mutated variants_x000D_ of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit_x000D_ recombinant vaccines. Braz J Infect Dis. 2021 Aug 17;25(4):101606._x000D_ _x000D_ 8: Calvignac-Spencer S, Budt M, Huska M, Richard H, Leipold L, Grabenhenrich L,_x000D_ Semmler T, von Kleist M, Kröger S, Wolff T, Hölzer M. Rise and Fall of SARS-_x000D_ CoV-2 Lineage A.27 in Germany. Viruses. 2021 Jul 29;13(8):1491._x000D_ _x000D_ 9: Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, Lürken K,_x000D_ Beigel A, Wrenger E, Lonnemann G, Cossmann A, Stankov MV, Dopfer-Jablonka A,_x000D_ Kaiser PD, Traenkle B, Rothbauer U, Krause G, Schneiderhan-Marra N, Behrens GMN._x000D_ Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on_x000D_ haemodialysis. EBioMedicine. 2021 Aug;70:103524._x000D_ 10: Makdasi E, Zvi A, Alcalay R, Noy-Porat T, Peretz E, Mechaly A, Levy Y,_x000D_ Epstein E, Chitlaru T, Tennenhouse A, Aftalion M, Gur D, Paran N, Tamir H,_x000D_ Zimhony O, Weiss S, Mandelboim M, Mendelson E, Zuckerman N, Nemet I, Kliker L,_x000D_ Yitzhaki S, Shapira SC, Israely T, Fleishman SJ, Mazor O, Rosenfeld R. The_x000D_ neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal_x000D_ antibodies is retained against viral variants. Cell Rep. 2021 Aug 21:109679._x000D_ _x000D_ Products Related to Biotinylated SARS-CoV-2 Spike RBD Alpha Variant : SARS-CoV-2

• Short Description:

  Catalog Number: B2010501 (25 ug)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5